Presentation is loading. Please wait.

Presentation is loading. Please wait.

LEVERAGING MINNESOTAS ASSETS TO BECOME THE DIABETES LABORATORY FOR THE WORLD Minnesota Senate Finance Committee May, 2013.

Similar presentations


Presentation on theme: "LEVERAGING MINNESOTAS ASSETS TO BECOME THE DIABETES LABORATORY FOR THE WORLD Minnesota Senate Finance Committee May, 2013."— Presentation transcript:

1 LEVERAGING MINNESOTAS ASSETS TO BECOME THE DIABETES LABORATORY FOR THE WORLD Minnesota Senate Finance Committee May, 2013

2 Text The Decade of Discovery (DoDD) was launched by Mayo Clinic and the University of Minnesota to conquer a disease with devastating physical, economic and social impacts: diabetes. Decade of Discovery aligns and integrates the significant resources and strengths of Mayo Clinic and the University through a disciplined, goal- directed approach to prevent, optimally treat and ultimately cure Type 1 and Type 2 diabetes. Decade of Discovery in Diabetes 2

3 Management Team Oversight Committee Susan Crockett, Ph.D. General Mills Michael Gorman, M.B.A, J.D. Split Rock Partners Chris Schaeffer American Diabetes Association, Minnesota Chapter Eric J. Jolly, Ph.D. Science Museum of Minnesota David M. Kendall, M.D. Eli Lilly Cindy Kent Medtronic, Inc. Dale Wahlstrom, M.S. LifeScience Alley and the BioBusiness Alliance of Minnesota David D. Etzwiler, J.D., M.P.P. – Executive Director Former Vice President of Community Affairs and Executive Director of the Medtronic Foundation Steven Smith, M.D. – Program Lead Medical Director for Patient Education, Mayo Clinic, past Chair of Diabetes Core Group: Division of Endocrinology, Diabetes, Nutrition, and Metabolism Maura Donovan, Ph.D. – Chief Technology Officer Former Vice President, Therapy R&D for Medtronic Corporate Ventures and New Therapies Elizabeth Seaquist, M.D. – Program Lead President-Elect, American Diabetes Association, professor, Department of Medicine in Division of Endocrinology and Diabetes at the University of MN Kathleen Blatz, M.S., J.D. Co-chair; former Chief Justice of the Minnesota Supreme Court Vance Opperman, J.D. Co-chair; Key Investment, Inc., MSP Communications Ann Albright, Ph.D., R.D. Centers for Disease Control and Prevention Richard M. Bergenstal, M.D. International Diabetes Center, American Diabetes Association (former President) Jackie Casey Juvenile Diabetes Research Foundation International (JDRF), Minnesota Chapter Frank B. Cerra, M.D. University of MN Leadership

4 Text More than 25 million Americans have diabetes; 79 million have prediabetes By 2020, estimates are that 52% of Americans will have diabetes or prediabetes DIABETES COSTS $3.1 billion annually in MN Estimated to grow to $6.4 billion by 2025 $200 billion in 2010 in U.S. Estimated to be more than $500 billion in 2020 Diabetes Impacts: Health and Costs 4 IN MINNESOTA - Diabetes doubled among adults since ,000 adults with diabetes in MN million adults with prediabetes - Every year 20,000 Minnesotans diagnosed - 6th leading cause of death - Risk of heart disease and stroke is 2-4 times higher than for those without - Leading complication among mothers giving birth IN MINNESOTA - Diabetes doubled among adults since ,000 adults with diabetes in MN million adults with prediabetes - Every year 20,000 Minnesotans diagnosed - 6th leading cause of death - Risk of heart disease and stroke is 2-4 times higher than for those without - Leading complication among mothers giving birth

5 Text Strong, goal-directed research with a focus on fast translation to a cure, employing team science that incorporates the best of academia and industry working together toward a common, transformative goal A mission-driven commitment to large-scale care delivery and prevention work with an understanding of system needs and the required alliances to impact those needs Rigorous governance and program management across scientific and clinical themes with clearly defined milestones and metrics The Vision: a Moonshot Combining academic research with the best of industry 5 Research Community Prevention Governance

6 Discovery and Translation Focus on Areas of Highest Promise Drug discovery: identify targets for intervention based on key metabolic and autoimmune processes and physiological mechanisms that underpin type 1 and type 2 diabetes Cell-biology based therapies: replace/sustain beta cell function through regeneration, reprogramming and replacement including beta cell biology, regenerative medicine, gene therapy, and transplantation Devices: accelerate technologies by combining biological, mathematical and engineering knowledge to develop novel ways to treat and deliver cures for diabetes 6 Rigorous RFP Process to Identify Lead Programs

7 Discovery and Translation Portfolio Approach 7 Discovery Pre- clinical (in vivo / animal studies) Phase 1 (1 st human dose to 1 st patient dose) Phase 2 (1 st patient dose to 1 st pivotal dose) Phase 3 (1 st pivotal dose to reg. submission) Regulatory Submission Probability of a substance moving to the next phase: varies ~55%~25%~70%~95% Approval Many ideas will be brought into the program to increase the chance of successProject plans will include go-no go criteria and well defined milestonesProgress against milestones will be regularly assessed

8 Discovery and Translation Leveraging Minnesotas Strengths to be a Center of Excellence 8 #1 in Diabetes & Endocrinology (2012 report) Industry and academic partnering is a priorityIndustry is looking for innovation # of diabetes patents is decreasing while incidence is escalating Historically, a majority of the novel pharmaceuticals comes from academia and biotech Different partnering models are being pursued All eyes will be on MN as a catalyst for innovation in diabetes therapy development

9 Prevention Strategy Minnesota Diabetes Collective Impact Initiative Decade co-leads statewide coalition with mission to become the state with the lowest incidence and the healthiest outcomes for diabetes in the nation. Prevention Strategy Identify, prioritize and scale evidence based interventions with the highest benefit for participants and public/private payers National Diabetes Prevention Program MN poised to be first state in the U.S. to implement NDPP on large scale 9 Collective Impact Participants include: American Diabetes AssociationBCBS of Minnesota Centers for Disease Control & Prevention Courage CenterDecade of Discovery Essentia Health Governors Task Force/Health CareHealthEast HealthPartners ICSIInternational Diabetes Center The Isuroon Project LifeScience AlleyMayo Clinic Health System Medica MN Community MeasurementMN Department of Health MN Health Action Group Minneapolis Urban LeagueNovo Nordisk Sanford Health System SEIU Healthcare MinnesotaStairstep Foundation Stratis Health Southside Community ClinicUcare UnitedHealth Group United WayUniversity of Minnesota West Side Community Health YMCA of the Greater Twin Cities

10 Text Through the Decade of Discovery, Minnesota has the opportunity to play a leadership role in a legacy project that will: Improve public health by transforming the lives of people with diabetes Deliver multi-billion dollar savings to the health care system, to employers, government payers and families by reigning in the huge and growing costs associated with diabetes Stimulate significant economic development – creating new businesses and jobs from our research The Goal: Improve Health, Save $ 10


Download ppt "LEVERAGING MINNESOTAS ASSETS TO BECOME THE DIABETES LABORATORY FOR THE WORLD Minnesota Senate Finance Committee May, 2013."

Similar presentations


Ads by Google